melanotan-2 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-29 and is reviewed periodically as new material appears.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
To the east and north of the rebuilt central city are a stretch of old neighbourhoods (Danton, Saint-Vincent, Graville, Massillon, etc.) which were spared the bombings of World War II. The buildings, usually in brick, dated to the 19th and the first half of the 20th centuries. The shops are concentrated along several major roads in the Rond-Point neighbourhood. During the 1990s and 2000s, these neighborhoods have seen major redevelopments, particularly in the context of an OPAH: improvement of habitat by rehabilitation or reconstruction, creation of public facilities, and revitalization of business. At the end of the 20th century and beginning of the 21st century, the area around the railway station has undergone a major transformation. As the station is the gateway to the city with the main avenues intersecting here. New buildings have sprung up (University of Le Havre, the conservatory, headquarters of the SPB (Provident Society Bank), and of CMA CGM, Novotel, Matmut, new CCI) some of which were designed by renowned architects. The bus station, certified NF since 2005, has been refurbished. North of the station, another construction project in place of the dilapidated island of Turgot-Magellan will be opened in 2013, including 12,500 m2 (135,000 sq ft) of office space and an eight-storey hotel, complete with shops on the ground-floor.
Note however that additives such as cobalt hexamine can produce exclusively intermolecular reaction, resulting in linear concatemers rather than the circular DNA more suitable for transformation of plasmid DNA, and is therefore undesirable for plasmid ligation. If it is necessary to use additives in plasmid ligation, the use of PEG is preferable as it can promote intramolecular as well as intermolecular ligation.
=== Treatment === Consumption of the death cap is a medical emergency requiring hospitalization. The four main categories of therapy for poisoning are preliminary medical care, supportive measures, specific treatments, and liver transplantation. Preliminary care consists of gastric decontamination with either activated carbon or gastric lavage; due to the delay between ingestion and the first symptoms of poisoning, it is common for patients to arrive for treatment many hours after ingestion, potentially reducing the efficacy of these interventions. Supportive measures are directed towards treating the dehydration which results from fluid loss during the gastrointestinal phase of intoxication and correction of metabolic acidosis, hypoglycemia, electrolyte imbalances, and impaired coagulation. No definitive antidote is available, but some specific treatments have been shown to improve survivability. High-dose continuous intravenous penicillin G has been reported to be of benefit, though the exact mechanism is unknown, and trials with cephalosporins show promise. Some evidence indicates intravenous silibinin, an extract from the blessed milk thistle (Silybum marianum), may be beneficial in reducing the effects of death cap poisoning. A long-term clinical trial of intravenous silibinin began in the US in 2010. Silibinin prevents the uptake of amatoxins by liver cells, thereby protecting undamaged liver tissue; it also stimulates DNA-dependent RNA polymerases, leading to an increase in RNA synthesis.
Overview of the RNAi process, from Cambridge University's The Naked Scientists Animation of the RNAi process, from Nature NOVA scienceNOW explains RNAi – A 15-minute video of the Nova broadcast that aired on PBS, 26 July 2005 Silencing Genomes Archived 10 August 2019 at the Wayback Machine RNA interference (RNAi) experiments and bioinformatics in C. elegans for education. From the Dolan DNA Learning Center of Cold Spring Harbor Laboratory. RNAi screens in C. elegans in a 96-well liquid format and their application to the systematic identification of genetic interactions (a protocol) 2 American 'Worm People' Win Nobel for RNA Work, from NY Times Molecular Therapy web focus: "The development of RNAi as a therapeutic strategy", a collection of free articles about RNAi as a therapeutic strategy. GenomeRNAi: a database of phenotypes from RNA interference screening experiments in Drosophila melanogaster and Homo sapiens RNAi tools Archived 19 June 2018 at the Wayback Machine Pre-designed and custom RNA Interference tools
Open fuel cycle: the cycle starts with the mining of uranium, goes through the fuel fabrication and ends with the direct disposal of the spent fuel. Closed fuel cycle: the spent fuel stored for a long time can be safely handled and it undergoes reprocessing in order to recover and recycle a large amount of it.
Sources: en.wikipedia.org
Over the next 11 years, she discovered that females only had the X chromosome and males had both X and Y chromosomes. She was able to conclude that sex is a chromosomal factor and is determined by the male. In 1911, Thomas Hunt Morgan argued that genes are on chromosomes, based on observations of a sex-linked white eye mutation in fruit flies. In 1913, his student Alfred Sturtevant used the phenomenon of genetic linkage to show that genes are arranged linearly on the chromosome.
== Background/History == Izon Science Limited is a company incorporated as Australo Ltd. on January 10, 2005, by four New Zealand-based scientists. In 2007, Hans van der Voorn became CEO, and on November 17, 2008, the company was renamed Izon Science Limited. Initially focused on developing tunable resistive pulse sensing instruments for nanoparticle characterization, the company later expanded into developing tools for isolating exosomes and other extracellular vesicles from biological fluids. Presently, Izon Science develops and manufactures tools for nanoparticle characterization and separation, catering to academic researchers and diagnostics companies working with extracellular vesicles, as well as those involved in nanomedicine, viruses, and virus-like particles. The Exoid is one of Izon's latest tunable resistive pulse sensing instruments, succeeding the qViro-X, qMicro, and qNano. In June 2021, Izon Science relocated its headquarters from Burnside (Christchurch) to a larger facility on Show Place, Addington (Christchurch). The company currently employs approximately 70 individuals. Izon has received investment funds from Bolton Equities, a privately funded investor group based in New Zealand. Research partnerships include the University Medical Center Utrecht and the VU University Medical Center in the Netherlands, the Mayo Clinic, the National Institutes of Health, and Massachusetts General Hospital.
C-type natriuretic peptide (CNP), the third hormone, was isolated from the swine brain and could relax smooth muscle. The three hormones share a similar structural makeup but come from different genes. These preliminary findings produced more investigation to establish the genetic makeup and regulatory mechanisms of these molecules.
The war on drugs, sometimes referred to in the 21st century as the war on cartels in contexts of military intervention and counterterrorism, is a global anti-narcotics campaign led by the United States federal government, ramped up after 9/11, including drug prohibition and foreign assistance, with the aim of reducing the illegal drug trade in the US. The initiative's efforts includes policies intended to discourage the production, distribution, and consumption of psychoactive drugs that the participating governments, through United Nations treaties, have made illegal. The term "war on drugs" was popularized by the media after a press conference, given on June 17, 1971, during which President Richard Nixon declared drug abuse "public enemy number one". Earlier that day, Nixon had presented a special message to the US Congress on "Drug Abuse Prevention and Control", which included text about devoting more federal resources to the "prevention of new addicts, and the rehabilitation of those who are addicted"; that aspect did not receive the same media attention as the term "war on drugs". In the years since, presidential administrations and Congress have generally maintained or expanded Nixon's original initiatives, with the emphasis on law enforcement and interdiction over public health and treatment. Cannabis presents a special case; it came under federal restriction in the 1930s, and since 1970 has been classified as having a high potential for abuse and no medical value, with the same level of prohibition as heroin.
==== Adipose tissue and metabolism ==== In obesity, white adipose tissue undergoes abnormal hypertrophic growth, leading to hypoxia and systemic inflammation. GLP-1 agonists mitigate this by downregulating lipogenic enzymes such as lipoprotein lipase (LPL) and ANGPTL4. Additionally, they promote the "browning" of energy-storing white adipose tissue into energy-burning brown adipose tissue. This metabolic shift is mediated by the activation of AMPK and SIRT1 pathways, which upregulate uncoupling protein 1 (UCP1) and increase cellular thermogenesis and energy expenditure. Some of the metabolic effects of GLP-1 agonists in rodents are also mediated via increased synthesis of fibroblast growth factor 21. Pharmaceutical companies have developed dual GLP-1/FGF21 receptor agonists.
Sources: en.wikipedia.org
In many European countries and elsewhere in the world, the most commonly found dihydrocodeine preparations are extended-release tablets made by encasing granules of the ingredient mixture, almost always using the bitartrate salt of dihydrocodeine, of four different sizes in a wax-based binder. The usual strengths are 60, 90, and 120 mg. Common trade names for the extended-release tablets are Didor Continus, Codidol, Codi-Contin, Dicodin (made in France and the major product containing the tartrate salt), Contugesic, DHC, and DHC Continus. Dihydrocodeine is available in Japan as tablets which contain 2.5 mg of dihydrocodeine phosphate and caffeine, the decongestant d,l-methylephedrine HCl, and the antihistamine chlorpheniramine, and packets of granules which effervesce like Alka-Seltzer with 10 mg of dihydrocodeine with lysozyme and chlorpheniramine, marketed for OTC sale as New Bron Solution-ACE. These two formulations may have once contained phenyltoloxamine citrate as the antihistamine component. Elsewhere in the Pacific Rim, Dicogesic in analogous to Glaxo/Smith-Kline's DF-118. The manufacturer of New Bron Solution-ACE; SS Pharmaceutical Co., Ltd, also markets an ibuprofen with dihydrocodeine product called S.Tac EVE, which also includes d,l-methylephedrine HCl, chlorpheniramine, anhydrous caffeine, and vitamins B1 and C. The Panlor series is manufactured by Pan-American Laboratories of Covington, Louisiana, and they also market several dihydrocodeine-based prescription cough syrups in the United States.
Because of its behavior as a prodrug and its pharmacokinetic differences, lisdexamfetamine has a longer duration of therapeutic effect than immediate-release dextroamphetamine and shows reduced misuse potential. CYP2D6, dopamine β-hydroxylase (DBH), flavin-containing monooxygenase 3 (FMO3), butyrate-CoA ligase (XM-ligase), and glycine N-acyltransferase (GLYAT) are the enzymes known to metabolize amphetamine or its metabolites in humans. Amphetamine has a variety of excreted metabolic products, including 4-hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, N-hydroxyamphetamine, benzoic acid, hippuric acid, norephedrine, and phenylacetone. Among these metabolites, the active sympathomimetics are 4-hydroxyamphetamine, 4-hydroxynorephedrine, norephedrine, and N-hydroxyamphetamine. The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination. The known metabolic pathways, detectable metabolites, and metabolizing enzymes in humans include the following:
Prince George's County Public Schools operates its bus system, providing student transportation. The fleet comprises various school bus models from Blue Bird Corporation, IC Bus, and Thomas Built Buses, all running on diesel. Accessible buses are available for special-needs children. All buses bear the Prince George's County Public Schools inscription. With 12 bus lots, the transportation department dispatches over 1,900 drivers and 1,200 buses on more than 5,000 routes. Annually, at least 83,000 students utilize these services. Routes are labeled with three-digit numbers like 615 or a combination of letters and numbers such as B12. Besides daily commuting, buses also serve school field trips, athletic events, and other sanctioned activities within Maryland and the region. Bus ridership is contingent on the student's distance from school, generally around two miles for intermediate/secondary schools and one and a half miles for primary institutions. Notably, the district offers students in magnet programs bus service throughout the county, with ridership not contingent on the student's proximity to school.
==== Abhidharma views of conditionality ==== The Buddhist abhidharma traditions developed a more complex schematization of conditionality than that found in the early sources. These systems outlined different kinds of conditional relationships. According to K.L. Dhammajoti, vaibhāṣika abhidharma developed two major schemes to explain conditional relations: the four conditions (pratyaya) and the six causes (hetu). The vaibhāṣika system also defended a theory of simultaneous causation. While simultaneous causation was rejected by the sautrāntika school, it was later adopted by yogācāra. The Theravāda abhidhamma also developed a complex analysis of conditional relations, which can be found in the Paṭṭhāna. A key element of this system is that nothing arises from a single cause or as a solitary phenomenon, instead there are always a plurality of conditions giving rise to clusters of dhammas (phenomena). The Theravāda abhidhamma outlines twenty four kinds of conditional relations.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.